The DOI matches its Crossref record.
Immunosuppressive Leflunomide Metabolite (A77 1726) Blocks TNF-Dependent Nuclear Factor-κB Activation and Gene Expression
Open accessAbstract
Leflunomide is a novel immunosuppressive and antiinflammatory agent currently being tested for treatment of autoimmune diseases and transplant rejection. NF-κB is a transcription factor activated in response to a wide variety of inflammatory stimuli, including TNF, but whether leflunomide blocks NF-κB activation is not known. In the present report we demonstrate that treatment of a human T cell line (Jurkat) with leflunomide blocks TNF-mediated NF-κB activation in a dose- and time-dependent manner, with maximum inhibition at 5–10 μM. Inhibition was not restricted to TNF-induced activation, because leflunomide also inhibited NF-κB activation induced by other inflammatory agents, including phorbol ester, LPS, H2O2, okadaic acid, and ceramide. Leflunomide blocked the degradation of IκBα and subsequent nuclear translocation of the p65 subunit, steps essential for NF-κB activation. This correlated with inhibition of dual specificity-mitogen-activated protein kinase kinase as well as an Src protein tyrosine kinase, p56lck, by leflunomide. Reducing agents did not reverse the effect of leflunomide. Leflunomide also suppressed the TNF-activated NF-κB-dependent reporter gene expression. Our results thus indicate that leflunomide is a potent inhibitor of NF-κB activation induced by a wide variety of inflammatory stimuli, and this provides the molecular basis for its anti-inflammatory and immunosuppressive effects.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Therapeutic strategies for rheumatoid arthritis
Smolen, J. S., & Steiner, G. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1109 · Cited by 911
Leflunomide: mode of action in the treatment of rheumatoid arthritis
Breedveld, F. C., & Dayer, J.-M. (2000) · Annals of the Rheumatic Diseases · doi:10.1136/ard.59.11.841 · Cited by 485
Wolfe, F., Caplan, L., & Michaud, K. (2006) · Arthritis & Rheumatism · doi:10.1002/art.21568 · Cited by 480
TNF ligands and receptors – a matter of life and death
MacEwan, D. J. (2002) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0704549 · Cited by 391
Next generation organofluorine containing blockbuster drugs
Han, J., Remete, A. M., Dobson, L. S., Kiss, L., Izawa, K., Moriwaki, H., Soloshonok, V. A., & O’Hagan, D. (2020) · Journal of Fluorine Chemistry · doi:10.1016/j.jfluchem.2020.109639 · Cited by 313
A new modality for immunosuppression: targeting the JAK/STAT pathway
O'Shea, J. J., Pesu, M., Borie, D. C., & Changelian, P. S. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1441 · Cited by 303
Herrmann, M. L., Schleyerbach, R., & Kirschbaum, B. J. (2000) · Immunopharmacology · doi:10.1016/s0162-3109(00)00191-0 · Cited by 273
Fuentealba, R. A., Marasa, J., Diamond, M. I., Piwnica-Worms, D., & Weihl, C. C. (2012) · Human Molecular Genetics · doi:10.1093/hmg/ddr500 · Cited by 28
Metadata
- Authors
- Manna, S. K., & Aggarwal, B. B.
- Venue
- The Journal of Immunology
- Publisher
- Oxford University Press (OUP)
- Published
- 1999-02
- Volume
- 162
- Issue
- 4
- Pages
- 2095-2102
- ISSN
- 0022-1767 (ISSN-L)
- 1550-6606
- OpenAlex
- W4313341534
- Cited by
- 187
- References
- 0
- FWCI
- 3.84
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.